Journal of infection and public health · 2025
Concentrated urine as an alternative to cervical smear samples enabling easy screening of HPV in large populations.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Uyar Neval Yurttutan, Bodur Harika, Erdem Merve Olcen, Altinisik Irem Ayse Kanneci, Aksoy Ece, Polat Tuba, Demir Figen, Acar Osman, Aksakal Boran, Alizade Gulnur, Nadirova Narmin, Apa Alara, Can Ozge, Kocagoz Tanil
Аннотация
BACKGROUND: Human Papillomavirus (HPV) infection is a leading cause of cervical cancer, necessitating effective screening methods, particularly in large populations and resource limited settings. Current cervical smear-based screening faces challenges related to accessibility, invasiveness, and patient compliance. This study investigated the feasibility of using concentrated urine samples as a noninvasive alternative for HPV detection.
METHODS: First-void urine samples from 126 patients were collected alongside cervical swabs. A biological fluid concentrator, MyMagiCon®, was used to concentrate the urine samples before HPV detection via RT-PCR.
RESULTS: The results demonstrated substantial agreement (Fleiss' kappa = 0.796, p < 0.0001) between HPV detection in concentrated urine samples and cervical smear samples. Concentrated urine samples showed a 17 % increase in HPV detection compared to unconcentrated urine.
CONCLUSIONS: This noninvasive and novel approach offers significant advantages in terms of accessibility and patient acceptance, potentially improving screening coverage and early detection rates, especially in underserved populations. Further research is needed to validate these findings in larger, more diverse populations and optimize the methodology for enhanced sensitivity and specificity, but the findings suggest concentrated urine-based HPV testing holds considerable promise as a cost-effective, accessible screening strategy in preventing cervical cancer.
METHODS: First-void urine samples from 126 patients were collected alongside cervical swabs. A biological fluid concentrator, MyMagiCon®, was used to concentrate the urine samples before HPV detection via RT-PCR.
RESULTS: The results demonstrated substantial agreement (Fleiss' kappa = 0.796, p < 0.0001) between HPV detection in concentrated urine samples and cervical smear samples. Concentrated urine samples showed a 17 % increase in HPV detection compared to unconcentrated urine.
CONCLUSIONS: This noninvasive and novel approach offers significant advantages in terms of accessibility and patient acceptance, potentially improving screening coverage and early detection rates, especially in underserved populations. Further research is needed to validate these findings in larger, more diverse populations and optimize the methodology for enhanced sensitivity and specificity, but the findings suggest concentrated urine-based HPV testing holds considerable promise as a cost-effective, accessible screening strategy in preventing cervical cancer.